Hepatitis B vaccine improves survival in patients with chronic liver disease

A new study shows that hepatitis B virus infection can have a positive impact on the survival of patients with chronic liver disease.²

Hepatitis B vaccines have previously been successful in preventing hepatitis B virus infection.According to the Hepatitis B Foundation, the hepatitis B virus vaccine is the safest and most effective vaccine ever developed ² Several studies have demonstrated the vaccine’s success in treating chronic liver disease.¹ The Centers for Disease Control and Prevention (CDC) says people with chronic liver disease (such as cirrhosis, fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) are at risk for hepatitis B infection.³

Led by Kaicen Wang from the Medical School of the University of Heidelberg in Mannheim, the researchers examined vaccination status in patients with chronic hepatitis C, non-alcoholic liver disease and cirrhosis. 1 Specifically, the researchers studied a large cohort of 57,306 patients at Columbia University between 2000 and 2020. , data collected from the Observational Health Data Science and Informatics Consortium. Nearly half of the patients (40.58%) had cirrhosis. Only 2.79% of patients with chronic liver disease were vaccinated, and 97.21% were not vaccinated.

“As 97.21% (55706/57306) of the population did not report immunization, further efforts must be made to improve the quality and comprehensiveness of medical records for patients with chronic liver disease,” the researchers wrote.

Researchers found that regardless of gender, patients with chronic liver disease who were vaccinated against the hepatitis B virus had significantly higher survival rates than those who were not vaccinated.ask =.000).

Although there was no impact on survival when patients had both hepatitis B and chronic hepatitis C, hepatitis B virus vaccination benefited patients with chronic hepatitis C. Here, survival rates improved significantly among vaccinated patients (ask =.000).

If patients have both hepatitis B virus and chronic non-alcoholic liver disease, their survival rates are worse. But patients with chronic non-alcoholic liver disease who received the hepatitis B virus vaccine had better survival rates (ask = .000, all; ask = .0003, female; ask = .007 for men).

The research team found that patients with cirrhosis had significantly improved survival rates (ask =.000). Both alcoholic and non-alcoholic cirrhosis derive significant benefit from hepatitis B virus vaccination (ask =.000).

“Our work shows that it is critical to expand coverage of universal (hepatitis B virus) vaccination programs, not only for patients at high risk of hepatitis B infection, but also for all patients with (chronic liver disease),” the researchers said. .” wrote.

^{refer to}

1. ^{Wang, K, Itzel, T, Daza, J., et al. Benefits of hepatitis B virus (HBV) vaccination in patients with chronic liver disease. AASLD Liver Meeting. November 10-14, 2023. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://vepimg.b8cdn.com/uploads/vjfnew/9655/content/images/1699677182file-pbubc020231110-20-20-20aasld-20poster-20 kaicen-20-20hepb-20vaccine- pdf1699677183.pdf. Accessed: November 21, 2023.}
2. ^{Hepatitis B vaccine. Hepatitis B Foundation. https://www.hepb.org/prevention-and-diagnosis/vaccination/. Accessed: November 21, 2023.}
3. ^{Adult vaccinations. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/hbv/vaccadults.htm. Accessed: November 21, 2023.}